Compare · MACK vs NVO
MACK vs NVO
Side-by-side comparison of Merrimack Pharmaceuticals Inc. (MACK) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MACK and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 3045.7x MACK ($62.8M).
- NVO has hit the wire 8 times in the past 4 weeks while MACK has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for MACK).
- Company
- Merrimack Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $15.15+0.10%
- $43.35+1.31%
- Market cap
- $62.8M
- $191.15B
- 1M return
- -
- -7.57%
- 1Y return
- -
- -44.83%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2012
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
Merrimack Pharmaceuticals Inc.
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MACK
- SEC Form 15-12G filed by Merrimack Pharmaceuticals Inc.
- SEC Form 10-Q filed by Merrimack Pharmaceuticals Inc.
- Vicore Expands and Strengthens its Board of Directors
- SEC Form 25 filed by Merrimack Pharmaceuticals Inc.
- SEC Form 8-K filed by Merrimack Pharmaceuticals Inc.
- Merrimack Pharmaceuticals Announces Approval Of Plan Of Dissolution And Cash Liquidating Dividend Amount Of $15.10 Per Share
- Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
- SEC Form DEFA14A filed by Merrimack Pharmaceuticals Inc.
- SEC Form 8-K filed by Merrimack Pharmaceuticals Inc.
- Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care